(2S)-2-icosa-5,8,11,14,17-pentaenoxybutanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-icosa-5,8,11,14,17-pentaenoxybutanoic acid
• 化学式: C₂₄H₃₈O₃
• 分子量: 374.6
• InChiKey: VOGXDRFFBBLZBT-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  27
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS<br/>[FR] DÉRIVÉS D'ACIDE GRAS POUR LE TRAITEMENT DE LA STÉATOHÉPATITE NON ALCOOLIQUE
  申请人：BASF AS

  公开号：WO2019111048A1

  公开（公告）日：2019-06-13

  The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

  本公开提供了一种用于治疗和/或预防非酒精性脂肪肝炎（NASH）和/或酒精性脂肪肝炎（ASH）的化合物。根据本发明使用的化合物是一种在β位含有氧原子的不饱和脂肪酸，并且还包含一个α-取代基。更具体地说，本发明提供了一种用于治疗NASH和/或ASH的化合物以及使用该方法，其中该化合物是公式（II），其中R1、R2、R3、X和Y如说明书中所定义；并且该化合物可以单独使用或与另一种活性剂结合使用。
• Novel lipid compounds
  申请人：Pronova BioPharma Norge AS

  公开号：EP2248798A1

  公开（公告）日：2010-11-10

  The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22 alkynyl having 1-6 triple bonds;R2 and R3 are the same or different and may be selected from a group of different substituents; and X represents a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.

  本发明涉及通式（I）的脂质化合物：其中R1选择自C10-C22烷基，具有1-6个双键的C10-C22烯基和具有1-6个三键的C10-C22炔基；R2和R3相同或不同，可以选择不同的取代基组成；X代表羧酸或其衍生物，如羧酸酯，羧酸酐或羧酰胺；或其药学上可接受的盐，溶剂化物，该盐的溶剂化物或其前药。本发明还涉及包含这些化合物的制药组合物和脂质组合物，以及将这些化合物用作药物或用于治疗，特别是用于治疗与心血管，代谢和炎症相关的疾病。
• POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS
  申请人：Hovland Ragnar

  公开号：US20120122940A1

  公开（公告）日：2012-05-17

  The present disclosure relates to lipid compounds of the general formula (I): R1-O—C(R2)(R3)-X  (I) wherein R 1 is a C 10 -C 22 alkyl group, a C 10 -C 22 alkenyl group having 1-6 double bonds, or a C 10 -C 22 alkynyl group having 1-6 triple bonds; R 2 and R 3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride, a phospholipid, triglyceride, or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic, and inflammatory disease area.

  本公开涉及一般式（I）的脂质化合物：R1-O-C（R2）（R3）-X（I），其中R1是C10-C22烷基，具有1-6个双键的C10-C22烯基，或具有1-6个三键的C10-C22炔基；R2和R3相同或不同，可以选择不同的取代基；X是羧酸或其衍生物，例如羧酸酯，羧酸酐，磷脂，甘油三酯或羧酰胺；或药学上可接受的盐，溶剂，该盐的溶剂或其前药。本公开还涉及包含至少一种根据本公开的化合物的制药组合物和脂质组合物，并涉及这些化合物的用途作为药物或用于治疗，特别是用于治疗与心血管，代谢和炎症相关的疾病领域。
• METHODS OF TREATMENT USING LIPID COMPOUNDS
  申请人：Hovland Ragnar

  公开号：US20130345269A1

  公开（公告）日：2013-12-26

  Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): or a pharmaceutically acceptable salt, or ester thereof, wherein R 1 and R 2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C 1 -C 6 alkyl groups, with the proviso that R 1 and R 2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL-cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.

  本文介绍了一种治疗或预防受试者至少一种疾病或病况的方法，包括给予式(I)化合物或其药学上可接受的盐或酯。其中，R1和R2是独立选择的氢原子或线性、支链和/或环状C1-C6烷基，但R1和R2不能同时为氢或其药学上可接受的盐或酯。这些疾病或病况可能涉及冠心病（CHD），例如动脉粥样硬化；代谢综合征/胰岛素抵抗；和/或血脂紊乱症，如高甘油三酯血症（HTG）、升高的LDL胆固醇、升高的总胆固醇、升高的载脂蛋白B和低HDL胆固醇。本文还提供了一种减少动脉粥样硬化发展的方法。同时，本文还揭示了包含式(I)化合物的药物组合物。
• Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
  申请人：BASF AS

  公开号：US11351139B2

  公开（公告）日：2022-06-07

  Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as SEDDS, SMEDDS, or SNEDDS comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid.

  包含 2-((5Z,8Z,11Z,14Z,17Z)-二十-5,8,11,14,17-五烯氧基)丁酸、酯衍生物或其药学上可接受的盐；甘油三酯；和表面活性剂的组合物及其使用方法。本公开进一步涉及自乳化给药系统，例如包含 2-((5Z,8Z,11Z,14Z,17Z)-二osa-5,8,11,14,17-pentaenyloxy)丁酸的 SEDDS、SMEDDS 或 SNEDDS。